recall
saveSamsung Bioepis Co., Ltd. recall (Cls II)
November 5, 2025updated 5mo ago
community read0 votes
HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01. — Reason: Lack of Assurance of Sterility. — Status: Ongoing
view source ↗Data sources
last refreshed 17m ago
Found something off?
same company · ±60 days · 6
- approvalEPYSQLI: EPYSQLI (ECULIZUMAB-AAGH) — FDA approvalNov 10, 2025
- approvalBYOOVIZ: BYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalNov 12, 2025
- approvaldenosumab biosimilar: DENOSUMAB-DSSB — FDA approvalOct 29, 2025
- approvalinfliximab biosimilar: RENFLEXIS (INFLIXIMAB-ABDA) — FDA approvalOct 28, 2025
- approvalPYZCHIVA: PYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalNov 18, 2025
- approvalPYZCHIVA: PYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalNov 18, 2025
🐶 often sniffed alongside
top 8- tagApproval128 co-mentions · 64 sources
- drugHADLIMA26 co-mentions · 13 sources
- drugPYZCHIVA26 co-mentions · 13 sources
- drugEPYSQLI20 co-mentions · 10 sources
- drugBYOOVIZ16 co-mentions · 8 sources
- drugustekinumab13 co-mentions · 13 sources
- drugadalimumab13 co-mentions · 13 sources
- drugHUMIRA13 co-mentions · 13 sources
comments(0)
5-min edit window · permanent after that